Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp
NCT05456854Phase 1Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2022
- Primary completion
- Aug 2024
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Kisspeptin-10 with Placebo (2 arms). Primary endpoints: First Phase Insulin Secretion at 10 minutes and Second Phase Insulin Secretion at 2 hours. Planned start Jun 2022; status: withdrawn.
02
Drugs
kisspeptin 112-121
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05456854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456854.